arrow
C

Christine M. McMahon

university of colorado school of medicine
H指数:29
被引数:4,292

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase 1/1b Study of the All-Oral Regimen CC-486 and Venetoclax in Acute Myeloid Leukemia

一项CC-486和Venetoclax口服方案在急性髓系白血病中的I/1b期研究

2026-07-280
OA
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia

Ziftomenib联合venetoclax和azacitidine在复发/难治性NPM1突变急性髓系白血病中的应用

Blood
IF23.1
2026-06-030
PRE
Tolerability and Outcomes With Serial Cycles of 28 Days of Venetoclax in Newly Diagnosed Patients With Acute Myeloid Leukemia

新诊断急性髓系白血病患者的耐受性与结局:接受连续28天周期性Venetoclax治疗的研究

2026-02-130
PRE
The STAT3-VDAC1 axis modulates mitochondrial function and plays a critical role in the survival of acute myeloid leukemia cells

STAT3-VDAC1轴调控线粒体功能并在急性髓系白血病细胞存活中发挥关键作用

2026-02-015
OA
Real-world analysis of CPX-351 in AML-MR: A multicentre study from the MARROW consortium

CPX-351在AML-MR中的真实世界分析:MARROW联盟的多中心研究

2025-12-010
OA
Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial

奥马曲拉和氮杂胞苷用于初治的伴有过多 blasts 的骨髓增生异常综合征患者的 I/II 期临床试验

2025-10-100
OAAI
Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

已知预后模型无法预测Venetoclax和Azacitidine在复发/难治性急性髓系白血病中的结局:一项单中心回顾性分析

2025-08-140
PREAI
Omacetaxine and Azacitidine for Newly Diagnosed Patients with Myelodysplastic Syndromes and Excess Blasts

奥马扎克汀和阿扎胞苷用于新诊断的伴有过多原始细胞的骨髓增生异常综合征患者

BLOOD
IF23.1
2024-11-050
PRE
Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Ziftomenib 与强化诱导 (7+3) 联合治疗新诊断的 NPM1-m 或 KMT2A-r 急性髓系白血病:KOMET-007 研究的期 1a 期中期结果

BLOOD
IF23.1
2024-11-055
PRE
Comparison of Myeloablative Conditioning with a Total Body Irradiation-Based Regimen Versus a Chemotherapy-Based Regimen in Adult Patients Undergoing Umbilical Cord Blood Stem Cell Transplant for Ph-Negative Acute Lymphoblastic Leukemia

比较清髓性预处理与基于全身照射的方案与基于化疗的方案在成年接受脐带血干细胞移植治疗Ph阴性急性淋巴细胞白血病患者中的对比

BLOOD
IF23.1
2024-11-050
PRE
A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy
2023-06-2631
OA
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia
2023-04-1311
OAAI
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7+3 Type Chemotherapy or Venetoclax/Azacitidine
2022-09-015
PRE
Myelodysplastic Syndromes, Version 3.2022 Featured Updates to the NCCN Guidelines
2022-02-0170
OA